Tagged with R&D

Pharma The below chart shows the sources of funding for R&D investment in Italy, with only 7% of total investment originating from pharmaceutical and health-oriented biotech. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…

Pharma France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a tradition of openness and understanding of dermatology. [France is] a unique environment for the growth of dermo-cosmetic brands. French dermatologists have a…

Pharma The following chart shows the number of clinical trials in Italy per year. Peaking in 2008 and slumping slightly shortly after, the numbers have returned to robust levels with 550+ trials in total in 2013 and 250+ important Phase I and II trials. Click here to read more articles and…

Pharma The following chart gives the key statistics on the Italian pharmaceutical industry; from number of manufacturing plants, to investments and export growth. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

Pharma Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. She also discusses supporting research in Switzerland through the Pfizer Research Prize Foundation, which celebrates its 25th anniversary in 2016. What have…

PPP Known as “Ireland’s university of Enterprise,” Dublin City University’s research and educational philosophy is very much informed by the institution’s strong partnerships and collaborations with the private sector. Professor Brian MacCraith discusses the institutions’ unique approach to academic-private collaborations and some of the initiatives currently underway in the life science…

Pharma Founded in 2011, APC has grown to be the largest process development company in Ireland. It is the largest employer of PhD Chemical Engineers nationally, is partners with the largest pharma and biotech companies globally, and over 80% of the company’s revenue is export driven. Since starting APC in 2011, what have been…

Health In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future. Could you give our international viewers an overview of…

Pharma Reckitt Benckiser’s General Manager for the CEE region, Lajos Magyari, discusses the strength of the company’s current portfolio, the importance of innovation and the success factors he focuses on to drive growth in the region. He outlines the company’s vision for 2020 and the significance of the health category segment.…

R&D Professor Dr. Robert Riener speaks about the much anticipated Cybathlon event and its importance to technology transfer, the Swiss education system’s ability to attract international talent, and his goals for the future. You have been leading the Department of Health Sciences and Technology at ETH Zurich since February 2016. Could…